Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haluska

Showing results (321-330 of 366) with videos related to

Pageof 37
Sort By:
International Journal of Hematology|April 27, 2017
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyArinobu Tojo, Taiichi Kyo, Kazuhito Yamamoto, et al.
Gynecologic Oncology|March 7, 2016
High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcomeEvan Delgado, Michelle M Boisen, Robin Laskey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical SpecimensCourtney L Andersen, Matthew J Sikora, Michelle M Boisen, et al.
Mayo Clinic Proceedings|July 11, 2008
Malignant melanoma in the 21st century: the emerging molecular landscapeAleksandar Sekulic, Paul Haluska, Arlo J Miller, et al.
Oncotarget|April 20, 2017
Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesMadalene A Earp, Rama Raghavan, Qian Li, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Scientific Reports|April 14, 2021
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) settingAnn L Oberg, Ethan P Heinzen, Xiaonan Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
Cancer Research|November 1, 1996
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanomaJ F Flores, G J Walker, J M Glendening, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Pageof 37

Showing results (321-330 of 366) with videos related to

Sort By:
Pageof 37
International Journal of Hematology|April 27, 2017
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyArinobu Tojo, Taiichi Kyo, Kazuhito Yamamoto, et al.
Gynecologic Oncology|March 7, 2016
High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcomeEvan Delgado, Michelle M Boisen, Robin Laskey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical SpecimensCourtney L Andersen, Matthew J Sikora, Michelle M Boisen, et al.
Mayo Clinic Proceedings|July 11, 2008
Malignant melanoma in the 21st century: the emerging molecular landscapeAleksandar Sekulic, Paul Haluska, Arlo J Miller, et al.
Oncotarget|April 20, 2017
Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypesMadalene A Earp, Rama Raghavan, Qian Li, et al.
The Lancet. Oncology|November 13, 2016
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trialScott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, et al.
Scientific Reports|April 14, 2021
Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) settingAnn L Oberg, Ethan P Heinzen, Xiaonan Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasSant P Chawla, Arthur P Staddon, Laurence H Baker, et al.
Cancer Research|November 1, 1996
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanomaJ F Flores, G J Walker, J M Glendening, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Pageof 37